What's in Pharmbio Korea Co., Ltd.'s pipeline?

Pharmbio Korea Co., Ltd. has 9 drugs in our index: 1 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Pharmbio Korea Co., Ltd.'s portfolio?

Top competitors by shared drug class: Bayer, Daewoong Pharmaceutical Co. LTD., Ahn-Gook Pharmaceuticals Co.,Ltd, Avalo Therapeutics, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pharmbio-korea-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pharmbio Korea Co., Ltd. — Portfolio Competitive Intelligence Brief

Pharmbio Korea Co., Ltd. pipeline: 1 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 7 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
OST	OST	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	Osteoporosis
PBK-1701TC	PBK-1701TC	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
PBK_L2201	PBK_L2201	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
PBK_M2502 1-Day	PBK_M2502 1-Day	phase 3	small molecule	unknown	unknown
PBK_M2502 2-Day	PBK_M2502 2-Day	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
PBK_M2101 2-Day	PBK_M2101 2-Day	phase 3
PBK_M2101 1-Day	PBK_M2101 1-Day	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Oral Sulfate Tablet 2-Day	Oral Sulfate Tablet 2-Day	phase 3	Osmotic laxative		Gastroenterology

Therapeutic area mix

Diabetes · 4
Gastroenterology · 1
Osteoporosis · 1
unknown · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Avalo Therapeutics, Inc. · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Daewon Pharmaceutical Co., Ltd. · 2 shared drug classes
AJU Pharm Co., Ltd. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Pharmbio Korea Co., Ltd.:

Cite this brief

Drug Landscape (2026). Pharmbio Korea Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmbio-korea-co-ltd. Accessed 2026-05-16.